In signal transduction research, protein kinase inhibitors help scientists tease out the vagaries of complex signaling pathways, but anecdotal evidence suggests that they are flawed tools at best, lacking the specificity necessary to draw conclusions from their use. Though experts agree that inhibitors have a legitimate place in science as screening tools, can researchers conduct good science on the carbon backbones of such agents?
Philip Cohen decided to find out. Cohen, Royal Society research professor and director of the Medical Research Council's protein phosphorylation unit, University...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?